

Poster Number	Abstract Reference	Poster Session	Category	Title	Presenting Author	
					First Name	Last Name
P 1	AROVA0004	1	VIR	Distribution of respiratory syncytial virus subtypes A and B among children presenting with acute respiratory tract infection to Kegalla hospital, Sri Lanka.	Maduja	Divarathna
P 2	AROVA0006	1	VIR	Prevalence of respiratory syncytial virus in acute respiratory tract infections in a selected sample of children from Sri Lanka	Maduja	Divarathna
P 3	AROVA0009	1	VIR	RSV Gene Expression Patterns Depend on Strain & Gene Start (GS) Signal N-Phase	Felipe-Andres	Piedra
P 4	AROVA0023	1	VIR	Surveillance of respiratory viruses in the outpatient setting in rural coastal Kenya: baseline epidemiological observations	Joyce	Nyiro
P 5	AROVA0053	1	VIR	In vitro characterization of subgroup A and B recombinant human respiratory syncytial viruses based on clinical isolates	Laurine	Rijsbergen
P 6	AROVA0056	1	VIR	In vivo comparison of recombinant human respiratory syncytial virus strains based on clinical isolates in cotton rats	Rik	de Swart
P 7	AROVA0058	1	VIR	Immunogold electron microscopy reveals that nucleolin (NCL) is recruited to the apical membrane of human airway epithelium by human RSV.	Peter	Mastrangelo
P 8	AROVA0066	1	VIR	Interaction of the RSV matrix protein with the viral transcriptase	Sarah	Croft
P 9	AROVA0075	1	VIR	Mathematical Modeling Identifies Adaptive Immunity as a Key Controller of Respiratory Syncytial Virus (RSV) Titer in Cotton Rats	Darren	Wethington
P 10	AROVA0081	1	VIR	Human metapneumovirus cell-to-cell spread in respiratory cell lines and 3D cultures	Nicolas	Cifuentes
P 11	AROVA0082	1	VIR	Differences in RSV Subtypes: Examination of fusion and effectiveness of fusion protein specific monoclonal antibodies	Chelsea	Barrett
P 12	AROVA0084	1	VIR	ELUCIDATION OF THE ROLES OF IRF9 AND IFI6 IN RESPONSE TO RSV INFECTION	Jonathon	Coe
P 13	AROVA0103	1	VIR	Stability and conformational transitions of the RSV nucleocapsid	Damián	Alvarez-Paggi
P 14	AROVA0112	1	VIR	Role of RSV Polymerase in the Antiviral Effect of Ribavirin	Amy	Fung
P 15	AROVA0121	1	VIR	Secretome profiling of airway epithelial cultures of paediatric origin infected with human respiratory syncytial virus (hRSV)	Olivier	Touzelet
P 16	AROVA0138	1	VIR	RSV strain-dependent growth kinetics, cytopathogenesis and innate immune responses following WD-PBEC infection.	Lindsay	Broadbent
P 17	AROVA0144	1	VIR	RSV attributable mortality in Portugal between 2014 and 2018	RAQUEL	GUIOMAR
P 18	AROVA0153	1	VIR	Epidemiology of Respiratory Syncytial Virus in Antananarivo, Madagascar, 2011-2017: genetic diversity and mechanism of seasonality.	Noroso	Razanajatovo
P 19	AROVA0157	1	VIR	Molecular Characterization of Circulating Respiratory Syncytial Virus (RSV) Genotypes in a Paediatric Clinic, Accra- Ghana	ANNA. ABA	KAFINTU-KWASHIE
P 20	AROVA0167	1	VIR	Molecular Characterization of Circulating Respiratory Syncytial Virus (RSV) Genotypes in a Paediatric Clinic, Accra- Ghana	ANNA. ABA	KAFINTU-KWASHIE
P 21	AROVA0184	1	VIR	A Mathematical Model to Predict Respiratory Syncytial Virus Kinetics in Infants	Sydney	Busch
P 22	AROVA0188	1	VIR	Differential pathogenesis of human metapneumovirus clinical isolates in mouse models	Yu	Zhang
P 23	AROVA0192	1	VIR	High-Throughput Next-Generation Sequencing of Human Respiratory Syncytial Virus Subgroups A and B	Lijuan	Wang
P 24	AROVA0193	1	VIR	International Network For Optimal Resistance Monitoring of RSV (INFORM RSV): An international study to determine the molecular heterogeneity of RSV in children (a ReSViNET study)	Annefle	Langedijk
P 25	AROVA0199	1	VIR	The RSV G protein interacts with CX3CR1 in THP-1 monocytes	Tiffany	King
P 26	AROVA0210	1	VIR	RSV infection of STAT2-/- Golden Syrian Hamsters Reproduces the Pathologic Outcomes of RSV Infection of Human Airways.	Raymond	Pickles
P 27	AROVA0217	1	VIR	Molecular Characteristics and Seasonality of Respiratory Viruses Detected from Children with Influenza Like Illness in Nepal	Bishnu Prasad	Upadhyay
P 28	AROVA0225	1	VIR	RSV infection in Normal Human Bronchial Epithelial cells induces filopodia and increases cell migration.	Masfique	Mehedi
P 29	AROVA0238	1	VIR	Determinants of survival time among patients who were admitted with respiratory infection and died in a county referral hospital in Kenya, 2016	Lilian	Mayieka
P 30	AROVA0241	1	VIR	Severe RSV infections in children and elderly during 2017/2018 winter season	RAQUEL	GUIOMAR
P 31	AROVA0246	1	VIR	RSV binds Streptococcus pneumoniae via PBP1a increasing its virulence and antibiotic sensitivity	Claire	Smith

Poster Number	Abstract Reference	Poster Session	Category	Title	Presenting Author	
P 32	AROVA0105	1	VIR	Antibody coated Liposomes for Transmucosal vaccination	Mani	Bhargava
P 33	AROVA0007	1	VTT	Evaluation of respiratory syncytial virus resistant mutants to a potent human monoclonal antibody targeting the conserved epitope on antigenic site IV of RSV F protein	Aimin	Tang
P 34	AROVA0057	1	VTT	Efficacy of a virus-like particle (VLP) Respiratory Syncytial Virus (RSV) vaccine candidates in naive and previously infected cotton rat dams and their offspring	Jorge	Blanco
P 35	AROVA0017	1	VTT	A Novel RSV Vaccine Design against Suppression of Vaccine Enhanced Disease	Bin	Wang
P 36	AROVA0032	1	VTT	Respiratory syncytial virus (RSV) entry is inhibited by serine protease inhibitor AEBSF when present during early stage infection.	Winke	Van der Gucht
P 37	AROVA0043	1	VTT	mRNA vaccines expressing forms of RSV-F protein are immunogenic and protective in rodent models of Respiratory Syncytial Virus infection	Amy	Espeseth
P 38	AROVA0049	1	VTT	An mRNA Based Vaccine Expressing RSV F is Immunogenic and Protective in Non-Human Primate Models of Respiratory Syncytial Virus Infection	Andrew	Bett
P 39	AROVA0055	1	VTT	VRC/NIAID/NIH	Lingshu	Wang
P 40	AROVA0059	1	VTT	Evaluation of antibody response and efficacy in cotton rats inoculated with historical RSV strains and challenged with contemporary strains	Annette	Machado
P 41	AROVA0098	1	VTT	Transplacental Antibody Transfer of Respiratory Syncytial Virus specific IgG in NHP mother-infant pairs	Michael	Citron
P 42	AROVA0067	1	VTT	Characterization of Potent RSV Neutralizing mAbs isolated from human memory B cells	Xiao	Xiao
P 43	AROVA0073	1	VTT	Labyrinthopeptin A1 and A2 efficiently inhibit cell entry of human respiratory syncytial virus in vitro and in vivo	Sibylle	Haid
P 44	AROVA0076	1	VTT	Murine pneumonia virus (MPV) expressing the respiratory syncytial virus (RSV) fusion F glycoprotein from a supernumerary gene is attenuated and immunogenic in rhesus macaques.	Shirin	Munir
P 45	AROVA0077	1	VTT	Effects of the CX3C motif and secreted form of human respiratory syncytial virus (RSV) G protein on immune responses to a parainfluenza virus vector expressing the RSV G protein	Bo	Liang
P 46	AROVA0080	1	VTT	Pre-Immunity to RSV in human subjects influences the magnitude and quality of response to RSV vaccination	Darin	Edwards
P 47	AROVA0083	1	VTT	Examining the effects of MEDI8897 on RSV infection of human bronchial cells and airway cultures	Jonathan	Kinder
P 48	AROVA0087	1	VTT	Development and Validation of a Next Generation Sequencing Assay for Detecting Low Level Variants of Respiratory Syncytial Virus	Fiona	Fernandes
P 49	AROVA0090	1	VTT	The adenoviral vector Ad26 expressing the RSV prefusion F protein shows high potency in preclinical models including neonatal non-human primates, and no predisposition to ERD in rodents, encouraging further development of this vaccine for young infants	Leslie	Van der Fits
P 50	AROVA0094	1	VTT	Standardization and Normalization of RSV Neutralization Data from the VRC317 Clinical Trial Using BEI Panel Sera and International Standard 16/284	Man	Chen
P 51	AROVA0095	1	VTT	Improving ability of RSV microneutralization assay to detect G-specific and cross-reactive neutralizing antibodies through immortalized cell line selection	Marina	Boukhalova
P 52	AROVA0096	1	VTT	RSV sequenced directly from infant respiratory secretions reveals selection of minor F protein sequence variants after minimal cell culture passage	Zhenghui	Li
P 53	AROVA0115	1	VTT	RSV 5C4 Prefusion-Specific Antibody Gene Transfer as a Method of RSV Prevention	Rebecca	Loomis
P 54	AROVA0117	1	VTT	Evidence for multiple protective antigenic sites in Respiratory Syncytial Virus G attachment protein in addition to the central conserved domain	Surender	Khurana
P 55	AROVA0126	1	VTT	Multimeric RSV Pre-F antigens presented on a ferritin nanoparticle elicit strong neutralizing responses in animal and human models	Kurt	Swanson
P 56	AROVA0136	1	VTT	Clinical development of a pediatric live-attenuated RSV vaccine lacking the G attachment protein	Pauline	Verdijk
P 57	AROVA0139	1	VTT	Comparative therapeutic potential of ALX-0171 and palivizumab against RSV Memphis 37 and BT2a clinical strains in a RSV/WD-PBEC model.	Lindsay	Broadbent
P 58	AROVA0141	1	VTT	Exciting therapeutic potential of ALX-0171 demonstrated in RSV-infected well-differentiated primary paediatric bronchial epithelial cell (WD-PBEC) cultures.	Lindsay	Broadbent
P 59	AROVA0142	1	VTT	A Statistical Model of RSV Disease in Neonates and Efficacy Prediction for Maternal Vaccines	Bing	Cai
P 60	AROVA0147	1	VTT	Developing SeVRSV as an RSV vaccine and dissecting influences of nuclear hormones on vaccine success	Julia	Hurwitz
P 61	AROVA0150	1	VTT	Characterization of highly potent human monoclonal antibodies targeting different antigenic sites on the pre-fusion RSV-F protein	Harald	Rouha
P 62	AROVA0151	1	VTT	The isolation and characterization of the Respiratory Syncytial Virus N0-P complex paves the way for the rational design of novel antivirals.	Marie	Galloux
P 63	AROVA0159	1	VTT	Structure of RSV-F antigen with a potent neutralizing antibody	Hua	Su

Poster Number	Abstract Reference	Poster Session	Category	Title	Presenting Author	
P 64	AROVA0164	1	VTT	Pre-clinical evaluation of MV-012-968, a live, attenuated respiratory syncytial virus vaccine candidate	Roderick	Tang
P 65	AROVA0170	1	VTT	Removal of single or double N-glycosylation sequons in p27 of the respiratory syncytial virus fusion protein elicits enhanced antibody responses after DNA immunization	Annelies	Leemans
P 66	AROVA0171	1	VTT	Small molecules targeting HRSV M2-1	Jingjing	CAO
P 67	AROVA0173	1	VTT	Functionality of anti-RSV F protein antibodies induced by immunisation with investigational respiratory syncytial virus (RSV) vaccine based on ChAd155 viral vector expressing RSV viral proteins F, N and M2-1 and impact of baseline anti-vector immunity in healthy adults.	Matthew	Snape
P 68	AROVA0181	1	VTT	Development of an ELISA-Based Assay to Evaluate Conformation-Specific Immune Responses to an mRNA-Based Vaccine Against Respiratory Syncytial Virus	Pedro J	Cejas
P 69	AROVA0182	1	VTT	In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine	Ernest	Maynard
P 70	AROVA0185	1	VTT	Antigenic Characterization Prefusionogenic Nanoparticle Vaccine, Prefusion, and Postfusion F against a Broad Range of Neutralizing Monoclonal Antibodies and Epitope Responses in Cotton Rats	Nita	Patel
P 71	AROVA0187	1	VTT	Respiratory Syncytial Virus (RSV) Prefusionogenic F Nanoparticle Vaccine Compared to Prefusion and Postfusion RSV F: Physical and Antigenic Structure, Immunogenicity, and Protection	Gale	Smith
P 72	AROVA0190	1	VTT	Feasibility Evaluation of Blow Fill Seal Process and Compatibility with Aluminum Phosphate Adjuvanted Recombinant RSV F Nanoparticle Vaccine for Maternal Immunization	Yen-Huei	Lin
P 73	AROVA0203	1	VTT	Binding Kinetics of RSVF Prefusionogenic Vaccine to Palivizumab and Serum Polyclonal Antibody	Hanxin	Lu
P 74	AROVA0208	1	VTT	Respiratory Syncytial Virus (RSV) G Protein Immunogens to Produce a Safe, Robust and Durable Immune Response	Harrison	Bergeron
P 75	AROVA0216	1	VTT	Respiratory Syncytial Virus infection in Infant Baboons Enhances Work of Breathing, Tidal Volume and Minute Ventilation.	Robert	Welliver
P 76	AROVA0220	1	VTT	Efficacy of ChAd155-RSV in the bovine challenge model when administered in the presence of maternal antibodies	Rineke	De Jong
P 77	AROVA0224	1	VTT	Structure-based design of a fully synthetic RSV vaccine candidate based on conformationally stabilized epitope mimetics and self-assembling lipopeptides	Arin	Ghasparian
P 78	AROVA0226	1	VTT	Using household social contact patterns to estimate transmission of respiratory syncytial virus within and between households of a rural coastal population in Kenya.	Moses	Kiti
P 79	AROVA0233	1	VTT	Generation of RSV M-based virus-like particles	Binh	Ha
P 80	AROVA0234	1	VTT	Structurally Informed Phylogenetic Models for RSV F Gene Providing Insight of Vaccine Design	Justin	Bahl
P 81	AROVA0239	1	VTT	The effectiveness of Trino-IB on rat infected with respiratory syncytial virus (RSV).	Elijah Kolawole	OLADIPO
P 82	AROVA0240	1	VTT	Enhancing the immunogenicity and attenuation of respiratory syncytial virus vaccine candidates by altering NS1 function	Michael	Teng
P 83	AROVA0250	1	VTT	Feasibility of evaluating the impact of RSV prevention in infancy on prevalence of asthma and recurrent wheeze among 10-14 year old Native American children	Jessica	Atwell
P 84	AROVA0252	1	VTT	Rational, stable attenuation of human respiratory syncytial virus for live vaccines by deletion and insertion of amino acids in the hinge region between the mRNA capping and methyltransferase domains of the large polymerase protein	Miaoge	Xue
P 85	AROVA0256	1	VTT	Selecting vaccine antigens against respiratory syncytial virus: glycoprotein modulation of antibody production through Toll-like receptor 4	Juan	Gutman
P 86	AROVA0258	1	VTT	Economic burden of RSV disease and cost-effectiveness of interventions against RSV in 72 Gavi eligible countries	Mark	Jit
P 87	AROVA0259	1	VTT	Selected plant derived compounds with anti RSV activity.	Cynthia	Mathew
P 88	AROVA0260	1	VTT	Characterization of a wild type hRSV human challenge stock (RSV-NICA) in cotton rats	Martin	Schutten
P 89	AROVA0261	1	VTT	An MVA based RSV vaccine protects mice against RSV challenge by inducing antibodies, including mucosal IgA, as well as T cell responses, all of which are required for complete protection	Kathrin	Endt
P 90	AROVA0020	2	CS	RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling for Predictions in Pediatric Patients	Luzelena	Caro
P 91	AROVA0029	2	CS	A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of a Respiratory Syncytial Virus (RSV) neutralizing monoclonal antibody (MK-1654) in Healthy Subjects	Antonios	Aliprantis
P 92	AROVA0086	2	CS	The p53 tumor suppressor enhances the innate immune response to RSV via a TLR8 SNP	Daniel	Menendez
P 93	AROVA0089	2	CS	Respiratory syncytial virus (RSV) and influenza infections in children under 2 years of age in Ulaanbaatar, Mongolia and relation to pneumococcal carriage.	Lien Anh Ha	Do
P 94	AROVA0093	2	CS	RSV-specific T Cell Responses in the Phase I Clinical Trial of the Stabilized Prefusion RSV F Subunit Protein DS-Cav1	Tracy	Ruckwardt
P 95	AROVA0097	2	CS	Molecular diagnostic and serological investigation of RSV in pediatric long term care facilities	Natalie	Thornburg

Poster Number	Abstract Reference	Poster Session	Category	Title	Presenting Author	
P 96	AROVA0099	2	CS	The Importance of Respiratory Syncytial Virus in the Young Febrile Infant Population	Erin	Nicholson
P 97	AROVA0109	2	CS	Digital biomarkers to detect respiratory sickness by measuring; activity, voice, and audible respiratory symptoms	Paul	Wacnik
P 98	AROVA0110	2	CS	INTERIM SAFETY AND IMMUNOGENICITY RESULTS FROM RSV PREFUSION F (DS-CAV1) SUBUNIT PROTEIN VACCINE PHASE I CLINICAL TRIAL (VRC 317)	Michelle	Crank
P 99	AROVA0119	2	CS	RESPIRATORY SYNCYTIAL VIRUS INFECTION IN THE HOMELESS POPULATION	Jim	Boonyaratanakornkit
P 100	AROVA0127	2	CS	Low rate of resistance to the RSV fusion Inhibitor RV521 in human infection	John	DeVincenzo
P 101	AROVA0130	2	CS	Maternal antibody titers to respiratory syncytial virus (RSV) pre-fusion F protein and risk of severe RSV bronchiolitis in infants	Octavio	Ramilo
P 102	AROVA0132	2	CS	Preliminary Antibody Repertoire Analysis of Memory B Cells from Stabilized Prefusion RSV F Subunit Protein (DS-Cav1)-Vaccinated Adult Volunteers	Maryam	Mukhamedova
P 103	AROVA0137	2	CS	Reduced nasal viral load and IFN responses in infants with severe RSV bronchiolitis	Peter	Openshaw
P 104	AROVA0160	2	CS	EDP-938, a Novel, Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus: Preliminary Results of a Phase 1 Study in Healthy Subjects (HS)	Nathalie	Adda
P 105	AROVA0163	2	CS	Comparison of Demographic and Clinical Characteristics and Outcome of RSV A vs. B.	Varvara	Probst
P 106	AROVA0174	2	CS	Immune responses after 12-month booster dose of MVA-BN-RSV	Christopher	Heery
P 107	AROVA0175	2	CS	A mixed methods approach to developing a bronchiolitis core outcome set	Paul	McNamara
P 108	AROVA0200	2	CS	Does prevention of RSV disease by monoclonal antibody result in rebound RSV disease?	Amanda	Driscoll
P 109	AROVA0212	2	CS	Potential role of IL-33 in the severity of Respiratory Syncytial Virus infection	Susan	Bueno
P 110	AROVA0227	2	CS	RSV-associated respiratory deaths among Zambian Infants: an interim analysis of the first year of the Zambia Pertussis RSV Infant Mortality Estimation (ZPRIME) Study.	Christopher	Gill
P 111	AROVA0229	2	CS	Development of EIA Assays to Detect and Quantify Antibody Response to Respiratory Syncytial Virus in Humans	Samadhan	Jadhao
P 112	AROVA0228	2	CS	The RSV Human Viral Challenge Model: Over a decade of experience, what have we learnt?	Rob	Lambkin-Williams
P 113	AROVA0230	2	CS	Human viral challenge model, A systematic analysis of placebo population data from six RSV studies	Nicolas	Noulin
P 114	AROVA0231	2	CS	Use of qualitative integrated Cyclor PCR to trigger therapeutic/placebo dosing in human experimental infection: a retrospective analysis	Nicolas	Noulin
P 115	AROVA0244	2	CS	The utilisation of enhanced assay strategies for the RSV human challenge model	Andrew	Catchpole
P 116	AROVA0243	2	CS	Longitudinal IFN- γ plasma concentrations and persistent wheezing in infants with RSV Bronchiolitis	Rosa	Rodriguez
P 117	AROVA0263	2	CS	RSV DISEASE IN INFANTS AND POLYMORPHISMS IN IFNAR1	Sofia	Laudanno
P 118	AROVA0135	2	CS	RESPIRATORY SYNCYTIAL VIRUS: POLICY REVIEW AND NEW PUBLIC HEALTH RISKS	Suzanne	Staebler
P 120	AROVA0010	2	EE	Risk factors associated with severe infection by Respiratory Syncytial Virus in children with Acute Bronchiolitis in Rionegro, Antioquia	Jefferson	Buendia
P 121	AROVA0011	2	EE	Burden of disease associated with respiratory syncytial virus infection in Colombia	Jefferson	Buendia
P 122	AROVA0024	2	EE	The health and economic burden of respiratory syncytial virus among children less than five years in New Zealand, 2012-2015	Namrata	Prasad
P 123	AROVA0025	2	EE	The health and economic burden of respiratory syncytial virus among adults aged 50 years or more in New Zealand, 2012-2015	Namrata	Prasad
P 124	AROVA0027	2	EE	Respiratory syncytial virus-associated severe respiratory illness among children	Meredith	McMorrow
P 125	AROVA0028	2	EE	Community burden and household transmission of respiratory syncytial virus (RSV) in a rural and an urban setting, South Africa, 2016-2017	Cheryl	Cohen
P 126	AROVA0030	2	EE	Evolutionary dynamics of respiratory syncytial virus genotype BA attachment (G) glycoprotein in Kilifi, coastal Kenya, 2003-2017	Everlyn	Kamau
P 127	AROVA0031	2	EE	Molecular characterization of respiratory syncytial virus in children with repeated infections with subgroup B in the Philippines	Michiko	Okamoto
P 128	AROVA0037	2	EE	Molecular characterization of respiratory syncytial viruses circulating in a pediatric cohort in Amman, Jordan	Nidia Isabel	Sequeira Trovao

Poster Number	Abstract Reference	Poster Session	Category	Title	Presenting Author	
P 129	AROVA0038	2	EE	Detection of RS virus and multiple respiratory viruses in inpatients with respiratory tract infection by direct real-time RT-LAMP.	Koichi	Hashimoto
P 130	AROVA0039	2	EE	Mortality Associated with Laboratory Confirmed RSV Infection, Connecticut, 2013-2016	Lindsay	Kim
P 131	AROVA0042	2	EE	Respiratory syncytial virus hospitalization during pregnancy in four high-income countries: Results from the PREVENT Network	Sarah	Buchan
P 132	AROVA0045	2	EE	Assessment of Respiratory Syncytial Virus Surveillance in the United States	Monica	Schroeder
P 133	AROVA0047	2	EE	Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States	Alexey	Ruzin
P 134	AROVA0054	2	EE	Association of respiratory syncytial virus (RSV) severity with candidate SNP variants using the Illumina Golden Gate genotyping platform	Jacqui	Marzec
P 135	AROVA0060	2	EE	Mortality in children in the community associated with acute respiratory infections	Mauricio	Caballero
P 136	AROVA0068	2	EE	Respiratory Syncytial Virus Burden of Disease and Lethality: 18 years active surveillance in a Pediatric Hospital	Maria Florencia	Lucion
P 137	AROVA0070	2	EE	Respiratory Syncytial Virus (RSV) in Preterm Infants: Epidemiology, Clinical Pattern and Risk Factors in a Pediatric hospital in Argentina.	Maria del Valle	Juarez
P 138	AROVA0071	2	EE	Prevalence of Human Respiratory Syncytial Virus in the Philippines, 1999-2016	Jonjee	Morin
P 139	AROVA0074	2	EE	Circulating strains of Human respiratory syncytial virus in Belgium during seven consecutive respiratory seasons (2011-2018)	Kaat	Ramaekers
P 140	AROVA0078	2	EE	Genetic analysis of human respiratory syncytial virus (RSV) F and G sequences from 2015-2017 in South Africa, implications for mAb/vaccine development	Hui	Liu
P 141	AROVA0092	2	EE	A model to estimate the potential impact of immunizations on respiratory syncytial virus (RSV) disease burden	Gayle	Langley
P 142	AROVA0101	2	EE	Long-Term Assessment of Healthcare Utilization Five Years After Respiratory Syncytial Virus Infection in US Infants	Eric	Simoes
P 143	AROVA0107	2	EE	Respiratory syncytial virus infection and disease in infants and young children (ages up to 10 years) observed in Rawalpindi, Pakistan.	Irum	Perveen
P 144	AROVA0113	2	EE	Respiratory syncytial virus A and B serotypes among patients hospitalised with severe respiratory illness, South Africa, 2012-2015	Ziyaad	Valley-Omar
P 145	AROVA0114	2	EE	Variation in Respiratory Syncytial Virus (RSV) gene sequence and its impact on viral clearance	Vasanthi	Avadhanula
P 146	AROVA0116	2	EE	Incidence and risk factors associated with respiratory syncytial virus acute respiratory infections in adults aged 65 years old and above residing in long-term care facilities in the Czech Republic (August 2003-May 2004 and August 2004-May 2005)	Thi Lien-Anh	Nguyen
P 147	AROVA0122	2	EE	Genetic variation of Respiratory Syncytial Virus predicts virulence and efficacy of immunoprophylaxis	Farah	Elawar
P 148	AROVA0125	2	EE	Whole genome analysis of local Kenyan and global sequences unravels the epidemiological and molecular evolutionary dynamics of RSV genotype ON1 strains	James	Otieno
P 149	AROVA0133	2	EE	Respiratory Syncytial Virus-Associated Hospitalizations in Young Children -- United States, 2015-2016	Brian	Rha
P 150	AROVA0134	2	EE	Epidemiology of Respiratory Syncytial Virus among Hospitalized Adults, United States, 2017-2018	Lindsay	Kim
P 151	AROVA0143	2	EE	The Burden of Respiratory Syncytial Virus (RSV) Febrile Illness and RSV-Associated Pneumonia within a Community-based Prospective Birth Cohort in Nicaragua	John	Kubale
P 152	AROVA0148	2	EE	Phylogenetic analysis of known epitopes in human respiratory syncytial virus F and G proteins	Yihui	Chen
P 153	AROVA0152	2	EE	Clinically significant viral respiratory disease in infancy is associated with early recurrent wheeze and asthma in a rural Ecuadorian birth cohort	Jessica	Atwell
P 154	AROVA0154	2	EE	Molecular and clinical characteristic of hospitalised respiratory syncytial virus (RSV) infections in children under 2 years of age in Melbourne.	Lien Anh Ha	Do
P 155	AROVA0166	2	EE	Burden and risk factors for severe human metapneumovirus disease in children from a developing country setting	Romina	Libster
P 156	AROVA0169	2	EE	In-host evolution of RSV during experimental infection of adult volunteers	Inne	Nauwelaers
P 157	AROVA0172	2	EE	RSV laboratory surveillance in the UK: building on existing ILI systems	Monica	Galiano
P 158	AROVA0178	2	EE	The First Laboratory Report of Respiratory syncytial viruses A/B (RSV A/B) among Acute Respiratory Illness Cases in Ethiopia, 2015-2016.	Adamu Tayachew	Mekonnen
P 159	AROVA0186	2	EE	A cluster of respiratory syncytial virus infections in a neonatal intensive care unit: Using molecular epidemiology to better understand transmission -- Louisiana, December 2017	Erica	Rose
P 160	AROVA0197	2	EE	Evolutionary analysis of four consecutive outbreaks of Respiratory Syncytial Virus using complete genomes from Argentina shows multiple introductions and subtype switch.	Stephanie	Goya

Poster Number	Abstract Reference	Poster Session	Category	Title	Presenting Author	
P 161	AROVA0198	2	EE	Epidemiology of respiratory syncytial virus infections reported through ILI and sARI surveillance in border province, Mongolia, 2013-2014.	Taro	Kamigaki
P 162	AROVA0214	2	EE	Molecular characterization of respiratory syncytial virus infections in children and adults in Seattle, WA from 2013 to 2016	Emily	Scott
P 163	AROVA0218	2	EE	Prevalence and seasonality of common viral respiratory pathogens, including Cytomegalovirus in children, between 0-5 years of age in KwaZulu-Natal, an HIV endemic province in South Africa.	Temitayo	Famoroti
P 164	AROVA0221	2	EE	Acute respiratory infections among school going children: Preliminary observations from a one-year longitudinal study.	Irene	Adema
P 165	AROVA0222	2	EE	The rate of laboratory confirmed RSV infection over five consecutive seasons in individuals aged 65 years or more	Chisha	Sikazwe
P 166	AROVA0237	2	EE	An evaluation of existing clinical case definitions for respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI)	Janet	Englund
P 167	AROVA0242	2	EE	Comparative Genomic Analysis of Human Respiratory Syncytial Virus Subgroups A and B from Nigeria	Elijah Kolawole	OLADIPO
P 168	AROVA0249	2	EE	National Center for Biotechnology Information (NCBI) human respiratory syncytial virus (HRSV) resources	Eneida	Hatcher
P 169	AROVA0253	2	EE	Molecular epidemiology of Respiratory Syncytial Virus across global and local scales	Justin	Bahl
P 170	AROVA0254	2	EE	A study to evaluate transmissibility among children aged under 5 years in households and its application to a cohort community in the Philippines	Hirono	Otomaru
P 171	AROVA0019	2	IMM	Vaccination with a single-cycle respiratory syncytial virus is immunogenic and protective in mice	Megan	Schmidt
P 172	AROVA0022	2	IMM	The role of short-chain fatty acids during Respiratory Syncytial Virus infection	Ana	Souza
P 173	AROVA0026	2	IMM	The impact of sequential overlapping infections with respiratory syncytial virus and influenza A virus on the host immune response and disease severity	Stacey	Hartwig
P 174	AROVA0034	2	IMM	Evaluation of a polyanhydride-based nanoparticle vaccine utilizing RSV M and/or prefusion F	Laura	Stephens
P 175	AROVA0035	2	IMM	Respiratory syncytial virus strain-dependent inflammasome activation influences pathogenesis	Kody	Waldstein
P 176	AROVA0061	2	IMM	The Human Respiratory Syncytial Virus Triggers p53-Dependent expression of innate immune APOBEC3 genes	Wesley	Gladwell
P 177	AROVA0064	2	IMM	PCA assay multi-laboratory study results show good output agreement for some assay formats and sample types	Nancy	Hosken
P 178	AROVA0079	2	IMM	Memory inflation drives tissue-resident memory CD8 T cell maintenance in the lung after intranasal vaccination with MCMV expressing RSV antigens	Kaitlyn	Morabito
P 179	AROVA0091	2	IMM	Differential expression of proteasome/immunoproteasome catalytic subunits by conventional dendritic cells contribute to the CD8 T cell hierarchy in RSV-infected mice	Anthony	DiPiazza
P 180	AROVA0140	2	IMM	Control of IFN-I responses by the aminopeptidase IRAP in neonatal alveolar macrophages upon RSV infection	Delphyne	Descamps
P 181	AROVA0146	2	IMM	CD32 expressing CD4-positive T cells during pediatric RSV infection	Inés	Sananez
P 182	AROVA0155	2	IMM	Respiratory Syncytial Virus Infection Predisposes Mice for Allergy-induced Asthma	Jozef	Balla
P 183	AROVA0162	2	IMM	A comparison of RSV F protein antibody repertoires in adenoids and peripheral blood from young children	Peter F.	Wright
P 184	AROVA0179	2	IMM	Development of Luciferase Immunoprecipitation Systems Assay (LIPS) to Detect IgG Antibodies against Human Respiratory Syncytial Virus G-Glycoprotein	Lynne	Crim
P 185	AROVA0202	2	IMM	Host genetic and microbial basis of Respiratory Syncytial Virus (RSV) infection outcomes in cotton rats.	Britton	Strickland
P 186	AROVA0205	2	IMM	Neutrophil apoptosis is delayed by RSV but increased following migration through RSV infected airway epithelial cells.	Elisabeth	Robinson
P 187	AROVA0207	2	IMM	A novel method of quantifying phagocytosis in neutrophils from infants with RSV.	Elisabeth	Robinson
P 188	AROVA0211	2	IMM	The investigation of early life innate immune responses to RSV in cystic fibrosis airway epithelium.	Patricia	Coulter
P 189	AROVA0219	2	IMM	Interferon-dependent and -independent control of Respiratory Syncytial Virus infection of respiratory epithelial cells	Philippa	Hillyer
P 190	AROVA0108	2	IMM	Pilot study on pulmonary delivery of Palivizumab for severe respiratory syncytial virus infections	Anushi	Rajapaksa